Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer :  A Multicenter International Cohort Study

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d4485082e649">Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. </p>

Related collections

Author and article information

Journal

Title: JAMA Oncology

Abbreviated Title: JAMA Oncol

Publisher: American Medical Association (AMA)

ISSN (Print): 2374-2437

Publication date (Electronic): November 04 2021

Affiliations

[1 ]Vanderbilt University Medical Center, Nashville, Tennessee

[2 ]Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

[3 ]Department of Surgery and Cancer, Imperial College London, London United Kingdom

[4 ]The University of Texas MD Anderson Cancer Center, Houston

[5 ]Zhongnan Hospital of Wuhan University, Wuhan, China

[6 ]Icahn School of Medicine at Mount Sinai, New York City, New York

[7 ]Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

[8 ]University of Kansas Cancer Center, Kansas City

[9 ]Case Western Reserve University, Division of Hematology & Oncology, Cleveland, Ohio

[10 ]Ohio State University, The James Comprehensive Cancer Center, Columbus

[11 ]Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas

[12 ]Duke Cancer Institute, Duke University, Durham, North Carolina

[13 ]The Ohio State University Comprehensive Cancer Center, Columbus

[14 ]Dana-Farber Cancer Center, Boston, Massachusetts

[15 ]Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

[16 ]Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

[17 ]Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy

[18 ]Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant’Andrea, Rome, Italy

[19 ]Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

[20 ]East Carolina University Brody School of Medicine, Division of Hematology & Oncology, Greenville, North Carolina

[21 ]Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio

[22 ]Policlinico Umberto I, Clinical and Molecular Department, Sapienza University of Rome, Rome, Italy

[23 ]IRCCS Istituto Tumori Giovanni Paolo II, Medical Thoracic Oncology Unit, Bari, Italy

[24 ]UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

[25 ]Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova, Genova, Italy

[26 ]Department of Surgery and Cancer, Imperial College London, London, United Kingdom

[27 ]Department of Translational Medicine, University of Piemonte Orientale “A. Avogadro”, Novara, Italy

[28 ]Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland

[29 ]Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City

Article

DOI: 10.1001/jamaoncol.2021.4960

PMC ID: 8569601

PubMed ID: 34734989

SO-VID: b4496d29-d45c-49c8-9ef9-477aee4fa42c

History

Data availability:

Comments

Comment on this article

scite_

Cited by 43

See all cited by

- Version 1

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer : A Multicenter International Cohort Study

Read this article at